EP1485103A1 — Sulfatase inhibiting continuous progestogen contraceptive regimens
Assigned to Janssen Pharmaceutica NV · Expires 2004-12-15 · 21y expired
What this patent protects
A method of contraception is described comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therapy including, for at most 35 successive days, the administration of a combination of an estrogen and a progestogen in a contra…
USPTO Abstract
A method of contraception is described comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therapy including, for at most 35 successive days, the administration of a combination of an estrogen and a progestogen in a contraceptively effective daily dosage wherein said progestogen is a potent sulfatase inhibiting progestogen and said cycle of therapy including 4-8 days in which said progestogen is administered in the absence of estrogen administration following said at most 35 successive days.
Drugs covered by this patent
- Estrace (ESTRADIOL) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.